Mucosis Announces Re-issue of Major Patent by US Patent Office USPTO
Patented technology applied in SynGEM, a needle-free nasal spray vaccine against respiratory syncytial virus * Re-Issuance of U.S. Patent...
top of page
Virtuvax News
SynGEM publication paper of the month on ReSViNET
#ReSViNET , the Respiratory Syncytial Virus Network, selected the recent publication in AJRCCM on the SynGEM Phase I clinical trial as...
First-in-Human Results of SynGEM Demonstrate that the RSV Vaccine Is Well-Tolerated and Capable of I
SynGEM a needle-free nasal spray vaccine against respiratory syncytial virus * SynGEM shown to be safe and immunogenic in healthy adults...
New comment by UMC Utrecht on the SynGEM vaccine trial is a plea to consider the vaccine in an RSV c
A new publication in the American Journal of Respiratory and Critical Care Medicine, headed by senior author prof. Louis Bont of UMC...
Phase I clinical trial data of Mucosis intranasal vaccine against respiratory syncytial virus (RSV)
Today phase I clinical trial data of the Mucosis intranasal RSV F protein vaccine were published on-line. The vaccine was shown to be...
Virtuvax to attend DCVMN in Kunming
Virtuvax consults in vaccine development and provides biosimilar and vaccine technologies. A most recent one, is the prefusion RSV-F...
Virtuvax for collaboration on your innovation in vaccine development or your biosimilar
Virtuvax will attend Bionnale 2017, 16 & 17th May 2017 in Berlin Germany. You can meet us there, discuss matchmaking and/or other...
Matchmaking and contributing to a vaccine based Global insurance against Emerging Infections?
21st and 22nd February our team will be present in Paris at the scientific community meeting of CEPI in which the urgency for action and...
Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”
Read the article written by Louis Garguilo of Outsourced Pharma about innovation in the vaccine industry and the role of our company...
bottom of page